EP3585420A4 - Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant - Google Patents

Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant Download PDF

Info

Publication number
EP3585420A4
EP3585420A4 EP18756867.0A EP18756867A EP3585420A4 EP 3585420 A4 EP3585420 A4 EP 3585420A4 EP 18756867 A EP18756867 A EP 18756867A EP 3585420 A4 EP3585420 A4 EP 3585420A4
Authority
EP
European Patent Office
Prior art keywords
peptides
methods
same
related disorders
dystrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18756867.0A
Other languages
German (de)
English (en)
Other versions
EP3585420A2 (fr
Inventor
Eytan R. Barnea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioIncept LLC
Original Assignee
BioIncept LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioIncept LLC filed Critical BioIncept LLC
Priority to EP22150813.8A priority Critical patent/EP4066850A3/fr
Publication of EP3585420A2 publication Critical patent/EP3585420A2/fr
Publication of EP3585420A4 publication Critical patent/EP3585420A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18756867.0A 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant Withdrawn EP3585420A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22150813.8A EP4066850A3 (fr) 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762462292P 2017-02-22 2017-02-22
PCT/US2018/019279 WO2018156801A2 (fr) 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP22150813.8A Division EP4066850A3 (fr) 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Publications (2)

Publication Number Publication Date
EP3585420A2 EP3585420A2 (fr) 2020-01-01
EP3585420A4 true EP3585420A4 (fr) 2021-04-07

Family

ID=63253026

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18756867.0A Withdrawn EP3585420A4 (fr) 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant
EP22150813.8A Withdrawn EP4066850A3 (fr) 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP22150813.8A Withdrawn EP4066850A3 (fr) 2017-02-22 2018-02-22 Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant

Country Status (6)

Country Link
EP (2) EP3585420A4 (fr)
CN (1) CN110869044A (fr)
AU (1) AU2018225163A1 (fr)
CA (1) CA3054366A1 (fr)
IL (1) IL268844A (fr)
WO (1) WO2018156801A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12254090B2 (en) 2021-08-26 2025-03-18 International Business Machines Corporation Filesystem object protection from ransomware attacks

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160263186A1 (en) * 2013-10-22 2016-09-15 Bioincept, Llc Pif-transfected cells and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404877B1 (fr) 2001-07-02 2010-01-06 Bioincept, LLC. Dosages pour le facteur preimplantatoire et peptides du facteur preimplantatoire
US8222211B2 (en) 2001-07-02 2012-07-17 Bioincept, Llc Methods of administering PIF agonist peptides and uses thereof
US7723290B2 (en) * 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
US7723289B2 (en) 2003-10-22 2010-05-25 Bioincept, Llc PIF tetrapeptides
EP1828224B1 (fr) 2004-12-22 2016-04-06 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
EP1793398A1 (fr) 2005-12-05 2007-06-06 Sokymat Automotive GmbH Dispositif de fixation pour und composant électronique et unité de fabrication avec table tournante
BRPI0708895A2 (pt) * 2006-03-13 2011-06-28 Liat Mintz uso de variante de junção de grelina para tratar caquexia e/ou anorexia e/ou anorexia-caquexia e/ou subnutrição e/ou lipodistrofia e/ou atrofia muscular e/ou estimulação do apetite
US8916532B2 (en) * 2008-04-28 2014-12-23 The Trustees Of The University Of Pennsylvania Methods for enhancing utrophin production via inhibition of microRNA
US8852940B2 (en) * 2009-04-01 2014-10-07 The Regents Of The University Of California Embryonic stem cell specific microRNAs promote induced pluripotency
KR20140037105A (ko) 2011-05-27 2014-03-26 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
AU2012320407B2 (en) 2011-10-07 2017-04-20 Bicyclerd Limited Modulation of structured polypeptide specificity
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
EP2850095B1 (fr) 2012-05-17 2019-10-09 RA Pharmaceuticals, Inc. Inhibiteurs peptidiques et peptidomimétiques
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2014138429A2 (fr) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leur utilisation dans la régulation de hif1alpha
CA2928235A1 (fr) * 2013-10-25 2015-04-30 Bush, Ernest D. Procedes de traitement de dystrophies musculaires
IL295025A (en) * 2014-09-16 2022-09-01 Bioincept Llc Preparations and methods for the treatment of acute radiation syndrome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160263186A1 (en) * 2013-10-22 2016-09-15 Bioincept, Llc Pif-transfected cells and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATRIZIA PESSINA ET AL: "Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy", SKELETAL MUSCLE, BIOMED CENTRAL LTD, LONDON, UK, vol. 4, no. 1, 25 August 2014 (2014-08-25), pages 7, XP021193544, ISSN: 2044-5040, DOI: 10.1186/2044-5040-4-7 *
UTPAL BASU ET AL: "Translational Regulation of Utrophin by miRNAs", PLOS ONE, vol. 6, no. 12, 27 December 2011 (2011-12-27), pages e29376, XP055751401, DOI: 10.1371/journal.pone.0029376 *

Also Published As

Publication number Publication date
EP4066850A3 (fr) 2022-11-23
EP3585420A2 (fr) 2020-01-01
WO2018156801A3 (fr) 2019-02-21
CA3054366A1 (fr) 2018-08-30
EP4066850A2 (fr) 2022-10-05
CN110869044A (zh) 2020-03-06
WO2018156801A2 (fr) 2018-08-30
AU2018225163A1 (en) 2019-09-19
IL268844A (en) 2019-10-31

Similar Documents

Publication Publication Date Title
EP3455322A4 (fr) Hydrofluorooléfines et leurs procédés d'utilisation
EP3429584A4 (fr) Compositions et méthodes de traitement de la presbytie
ZA201905851B (en) Peptides and methods for the treatment of diabetes
EP3348273B8 (fr) Compositions à base de protéines et de xyloglucane pour le traitement de troubles intestinaux
EP3245241A4 (fr) Polyélectrolytes conjugués et leurs procédés d'utilisation
EP3755148A4 (fr) Nanosuspensions de salsalate et leurs procédés d'utilisation
EP3377085A4 (fr) Peptides et méthodes de traitement de l'endométriose utilisant lesdits peptides
EP3313427A4 (fr) Peptides thérapeutiques et leurs procédés d'utilisation
EP3258930A4 (fr) Oxabicycloheptanes et oxabicycloheptènes permettant de traiter des troubles dépressifs et de stress
EP3691748A4 (fr) Combinaisons d'acétaminophène-prégabaline et procédés de traitement de la douleur
EP3651606A4 (fr) Revêtements de pierres précieuses et procédés de fabrication et d'utilisation associés
EP3472196B8 (fr) Vecteurs exprimant des neuropeptides et procédés pour le traitement de l'épilepsie
EP3341739A4 (fr) Peptides mutants et procédés de traitement de sujets les employant
EP3334730A4 (fr) Pyrrolomycines et leurs procédés d'utilisation
EP3500274A4 (fr) Méthodes et compositions de traitement des verrues
IL268844A (en) Peptides and methods of treating dystrophy-related diseases by them
HK40021181A (en) Peptides and methods of treating dystrophy-related disorders using the same
EP3265482A4 (fr) Protéine de ciblage d'intégrine et procédés pour l'utiliser
HK40048227A (en) Therapeutic uses and methods
HK40034329A (en) Compositions and methods for the treatment of allergy
HK40017878A (en) Multibiotic agents and methods of using the same
AU2018901531A0 (en) Therapeutic uses and methods
HK40018947A (en) Peptides and methods for the treatment of diabetes
HK40039258A (en) Cytobiologics and therapeutic uses thereof
HK40033822A (en) Therapeutic protein compositions and methods of making and using the same

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190917

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40021181

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/10 20060101ALI20201127BHEP

Ipc: A61K 45/06 20060101ALI20201127BHEP

Ipc: A61K 38/04 20060101ALI20201127BHEP

Ipc: A61K 38/17 20060101ALI20201127BHEP

Ipc: A61K 38/08 20190101ALI20201127BHEP

Ipc: A61P 21/00 20060101ALI20201127BHEP

Ipc: A61K 38/19 20060101AFI20201127BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210309

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/19 20060101AFI20210302BHEP

Ipc: A61K 38/10 20060101ALI20210302BHEP

Ipc: A61K 45/06 20060101ALI20210302BHEP

Ipc: A61K 38/17 20060101ALI20210302BHEP

Ipc: A61K 38/08 20190101ALI20210302BHEP

Ipc: A61K 38/04 20060101ALI20210302BHEP

Ipc: A61P 21/00 20060101ALI20210302BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220901